GlassScriptPhysician profile
Steven W Stetson
NPI 1487603411
$6,602.55
in general payments reported to CMS, 2019-2025
22 companies · $750 in 2025
The $750 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,997 · 2020: $289 · 2021: $977 · 2022: $1,110 · 2023: $974 · 2024: $505 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,228.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,068.27 | 2020-2025 | Kxl System (Not Refurbished), Ce-Marked Kxla System, Photrexa Viscous and Photrexa |
| Nidek Incorporated | $1,000.00 | 2019 | |
| Sun Pharmaceutical Industries INC. | $952.51 | 2019-2024 | Cequa |
| Oyster Point Pharma, INC. | $561.01 | 2022-2024 | Tyrvaya, Ryzumvi, Ryzumvi |
| Kala Pharmaceuticals, INC. | $361.77 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $302.74 | 2019-2025 | Tecnis Iol, Star S4 Ir |
| Novartis Pharmaceuticals Corporation | $285.50 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $266.49 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Sight Sciences, INC. | $256.98 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $242.25 | 2019-2021 | |
| Shire North American Group INC | $195.88 | 2019 | |
| Alcon Vision LLC | $185.35 | 2022-2025 | Centurion, Tryptyr |
| Rxsight INC | $156.25 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Tarsus Pharmaceuticals, INC. | $154.65 | 2025 | Xdemvy |
| Carl Zeiss Meditec, INC. | $146.54 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $125.00 | 2019 | |
| Eyepoint US, INC. | $124.92 | 2019 | |
| Ivantis, INC | $105.26 | 2021 | |
| Allergan, INC. | $36.55 | 2021-2022 | |
| Dompe US, INC. | $27.26 | 2025 | Oxervate |
| Rayner Intraocular Lenses Limited | $24.31 | 2025 | Rayone Spheric, Rayner Cataract Set 1, Rayone Emv |
| Eyevance Pharmaceuticals LLC | $23.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Stetson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.